# Cross-Run Convergence Report

**Generated**: 2026-02-13 00:55 UTC
**Runs analyzed**: 7
**Total claims**: 65
**Cross-matches found**: 30

## Runs

| Session | Domain | S3 | Claims |
|---------|--------|----|--------|
| evo_20260210_232904_pharmacology | pharmacology | FAIL | 13 |
| evo_20260210_235609_pharmacology | pharmacology | FAIL | 9 |
| evo_20260211_024747_pharmacology | pharmacology | FAIL | 9 |
| evo_20260211_024750_neuroscience | neuroscience | FAIL | 7 |
| evo_20260211_201329_pharmacology+bioelectric | pharmacology+bioelectric | FAIL | 10 |
| evo_20260212_032819_pharmacology | pharmacology | FAIL | 7 |
| evo_20260213_004656_consciousness | consciousness | FAIL | 10 |

## Cross-Validated Singulars

### CROSS-VALIDATED SINGULAR (cosine=0.7765)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): Lithium neuroprotection at low dose (<0.5 mM) primarily via partial GSK3β inhibition (IC50 1-2 mM), stabilizing β-catenin, upregulating BDNF and autop
- **Run B** (evo_20260210_235609_pharmacology, TYPE 0): 2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3β inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~

### CROSS-VALIDATED SINGULAR (cosine=0.6874)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): Therapeutic index TD50_nephro/ED50_neuro >10, with ED50_neuro ≈0.3 mM serum equiv., TD50>3 mM.
- **Run B** (evo_20260210_235609_pharmacology, TYPE 2): 4:** The clinical therapeutic index (~2–3) dramatically underestimates the *brain-specific* TI because brain [Li⁺] at toxic plasma levels (~1.5 mM) re

### CONVERGENT SINGULAR (cosine=0.6824)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): The dose-response curve for nephrotoxicity follows a Hill coefficient >1 (n ≈ 2–3), reflecting cooperative depletion of inositol pools, creating a ste
- **Run B** (evo_20260210_235609_pharmacology, TYPE 3): 3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n ≈ 1.5–2.5) because damage requires simultaneous IMPase inhibition (Ki

### CROSS-VALIDATED SINGULAR (cosine=0.6625)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): 2**: Therapeutic-dose lithium (>1.0 mM serum) induces nephrotoxicity via inositol monophosphatase (IMPase) inhibition, causing inositol depletion and 
- **Run B** (evo_20260210_235609_pharmacology, TYPE 2): 2:** *Nephrotoxicity arises from intracellular [Li⁺] trapping in renal principal cells (2–20× plasma levels) due to ENaC-mediated uptake and poor Na⁺/

### CONVERGENT SINGULAR (cosine=0.6574)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): Therapeutic index TD50_nephro/ED50_neuro >10, with ED50_neuro ≈0.3 mM serum equiv., TD50>3 mM.
- **Run B** (evo_20260210_235609_pharmacology, TYPE 3): Dose-discrepancy from PK-driven TI expansion: effective brain TI_GSK3 ~20-50 (ED50_plasma 0.2 mM / TD50_plasma 10 mM), renal TI_ENaC ~2-3 due to 5× ac

### CROSS-VALIDATED SINGULAR (cosine=0.6489)
- **Run A** (evo_20260211_201329_pharmacology+bioelectric, TYPE 2): 3:** The cytotoxic transition occurs NOT at depolarized ΔΨm but at **hyperpolarized** ΔΨm (~-180 mV), where VDAC1 partial closure promotes oligomeriza
- **Run B** (evo_20260212_032819_pharmacology, TYPE 3): 1:** The neuroprotection-to-cytotoxicity transition follows a cooperative oligomerization threshold: apoptosis requires ≥4 adjacent cofactor-free VDAC

### CROSS-VALIDATED SINGULAR (cosine=0.6447)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): Nephrotoxicity at therapeutic dose (0.8-1.5 mM) driven by IMPase inhibition (IC50 0.3-0.6 mM), causing myo-inositol depletion critical for renal AQP2 
- **Run B** (evo_20260210_235609_pharmacology, TYPE 2): 2:** *Nephrotoxicity arises from intracellular [Li⁺] trapping in renal principal cells (2–20× plasma levels) due to ENaC-mediated uptake and poor Na⁺/

### CROSS-VALIDATED SINGULAR (cosine=0.6446)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): The dose-response curve for nephrotoxicity follows a Hill coefficient >1 (n ≈ 2–3), reflecting cooperative depletion of inositol pools, creating a ste
- **Run B** (evo_20260210_235609_pharmacology, TYPE 1): Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li⁺ accumulation past a critical threshold (~

### CROSS-VALIDATED SINGULAR (cosine=0.6365)
- **Run A** (evo_20260211_201329_pharmacology+bioelectric, TYPE 1): Cytoprotective CBD (EC50 2-3.7 μM via TRPV1/2) dominates daytime (hyperpolarized ψ closes VDAC1, blocking cytotoxicity); nighttime flip via open VDAC1
- **Run B** (evo_20260212_032819_pharmacology, TYPE 3): The therapeutic window for a neuroprotective VDAC1 ligand like CBD is practically non-existent due to off-target effects. The neuroprotective concentr

### CROSS-VALIDATED SINGULAR (cosine=0.6341)
- **Run A** (evo_20260211_024747_pharmacology, TYPE 3): THC β-arrestin recruitment EC50 > G-protein EC50 (bias factor ~3-5), so low occupancy (<30%) yields therapeutic cAMP inhibition without GRK2/βarr down
- **Run B** (evo_20260211_024750_neuroscience, TYPE 0): 1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while

### CROSS-VALIDATED SINGULAR (cosine=0.6246)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): Hill coefficient n=1 for both effects governs hyperbolic switch; intracellular [Li] window [1-10]uM for peak protection before toxicity onset.
- **Run B** (evo_20260210_235609_pharmacology, TYPE 1): Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li⁺ accumulation past a critical threshold (~

### CONVERGENT SINGULAR (cosine=0.6226)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): Nephrotoxicity at therapeutic dose (0.8-1.5 mM) driven by IMPase inhibition (IC50 0.3-0.6 mM), causing myo-inositol depletion critical for renal AQP2 
- **Run B** (evo_20260210_235609_pharmacology, TYPE 3): 3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n ≈ 1.5–2.5) because damage requires simultaneous IMPase inhibition (Ki

### CROSS-VALIDATED SINGULAR (cosine=0.6194)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): Lithium neuroprotection at low dose (<0.5 mM) primarily via partial GSK3β inhibition (IC50 1-2 mM), stabilizing β-catenin, upregulating BDNF and autop
- **Run B** (evo_20260210_235609_pharmacology, TYPE 2): 4:** The clinical therapeutic index (~2–3) dramatically underestimates the *brain-specific* TI because brain [Li⁺] at toxic plasma levels (~1.5 mM) re

### CROSS-VALIDATED SINGULAR (cosine=0.6176)
- **Run A** (evo_20260211_201329_pharmacology+bioelectric, TYPE 1): Circadian depolarized ΔΨm (-165 mV nighttime) lowers CBD cytotoxic IC50 3-5x (to 3-5 μM from 15 μM daytime), enabling sub-Kd (11 μM) toxicity via VDAC
- **Run B** (evo_20260212_032819_pharmacology, TYPE 3): The therapeutic window for a neuroprotective VDAC1 ligand like CBD is practically non-existent due to off-target effects. The neuroprotective concentr

### CROSS-VALIDATED SINGULAR (cosine=0.6171)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 3): The dose-dependent switch is governed by the biphasic modulation of inositol monophosphatase (IMPase) and GSK-3β; low-dose inhibition is submaximal (~
- **Run B** (evo_20260210_235609_pharmacology, TYPE 0): 2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3β inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~

### CROSS-VALIDATED SINGULAR (cosine=0.6035)
- **Run A** (evo_20260210_232904_pharmacology, TYPE 2): Dose-switch via tissue context: neurons activate Nrf2/BDNF (low-dose induced) buffering mild inositol depletion; renal cells lack robust compensation,
- **Run B** (evo_20260210_235609_pharmacology, TYPE 3): The primary mechanism for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li⁺] (therapeut

### CROSS-VALIDATED SINGULAR (cosine=0.6023)
- **Run A** (evo_20260211_024747_pharmacology, TYPE 3): The tolerance crossover point is governed by first-order kinetics: therapeutic window persists while k_recycle + k_synthesis > k_int × fractional_occu
- **Run B** (evo_20260211_024750_neuroscience, TYPE 0): 1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while

## Independent Replications

- **cosine=0.6637** | evo_20260211_024747_pharmacology ↔ evo_20260211_024750_neuroscience
  A: 3:** Sustained wellbeing requires *synergistic 2-AG signaling*: low-dose THC (≤2.5 mg/day) adds to tonic 2-AG without di
  B: 1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-

- **cosine=0.6365** | evo_20260210_232904_pharmacology ↔ evo_20260210_235609_pharmacology
  A: (Supporting SINGULAR thread) Neuronal BDNF/TrkB signaling is potentiated by low-dose lithium via GSK-3β inhibition and C
  B: 2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3β inhibition via Akt-Ser9 phosphorylation amplif

## Cross-Promoted (TYPE 2 → validated)

- **cosine=0.7914** | evo_20260211_024747_pharmacology (T2) ↔ evo_20260211_024750_neuroscience (T0)
  A: 1:** Chronic low-dose THC (≤2.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 
  B: 1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-

- **cosine=0.6921** | evo_20260211_024747_pharmacology (T2) ↔ evo_20260211_024750_neuroscience (T0)
  A: 1:** Chronic low-dose THC (≤2.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 
  B: Aged hippocampus shows pathologically elevated GABAergic tone, such that low-dose THC (CB1 on interneurons) restores bal

- **cosine=0.6644** | evo_20260210_232904_pharmacology (T2) ↔ evo_20260210_235609_pharmacology (T0)
  A: The therapeutic index of lithium is fundamentally narrow because the Kᵢ for GSK-3β inhibition is only one to two orders 
  B: 2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3β inhibition via Akt-Ser9 phosphorylation amplif

- **cosine=0.6246** | evo_20260211_201329_pharmacology+bioelectric (T1) ↔ evo_20260212_032819_pharmacology (T2)
  A: Cytoprotective CBD (EC50 2-3.7 μM via TRPV1/2) dominates daytime (hyperpolarized ψ closes VDAC1, blocking cytotoxicity);
  B: 3:** The biphasic response is mechanistically distinct at low vs. high occupancy: sub-Kd CBD (<5 µM) allosterically enha

- **cosine=0.6013** | evo_20260211_201329_pharmacology+bioelectric (T2) ↔ evo_20260212_032819_pharmacology (T1)
  A: 3:** The cytotoxic transition occurs NOT at depolarized ΔΨm but at **hyperpolarized** ΔΨm (~-180 mV), where VDAC1 partia
  B: The cytotoxic threshold for VDAC1 ligands scales as Kd × (1 + [HK-II]/Ki_HK) × (Bcl-xL/Bax) × (1 + [tubulin]/Ki_tub), yi

## Structural Patterns (Isomorphism)

- **two_pathway**: evo_20260210_232904_pharmacology, evo_20260212_032819_pharmacology
- **threshold_crossover**: evo_20260210_232904_pharmacology, evo_20260210_235609_pharmacology, evo_20260211_024747_pharmacology, evo_20260211_024750_neuroscience, evo_20260212_032819_pharmacology
- **dose_dependent**: evo_20260210_232904_pharmacology, evo_20260211_024747_pharmacology, evo_20260212_032819_pharmacology

## Cosine Distribution (cross-run pairs)

- Min: -0.1937
- Median: 0.2526
- Mean: 0.2411
- Max: 0.7914
- N pairs: 1798
